IDH2 and central nervous system cancer: Furthermore, molecular genetic factors, notably 1p/19q codeletion and IDH mutation status, had a strong prognostic value in the classification of gliomas in the past but, since 2016, have become disease-defining features and are therefore no longer prognostic within a given disease subtype.